Literature DB >> 36267108

Coronary artery disease in patients with cystic fibrosis - A case series and review of the literature.

Zahrae Sandouk1, Noura Nachawi2, Richard Simon3, Jennifer Wyckoff1, Melissa S Putman4, Sarah Kiel5, Sarah Soltman6, Antoinette Moran7, Amir Moheet8.   

Abstract

Progressive obstructive pulmonary disease is the primary life-shortening complication in people with Cystic Fibrosis (CF); improvement in life expectancy has led to increased prevalence of non-pulmonary complications. Patients with CF are considered to be at low risk for coronary artery disease (CAD). We report here a case series of six patients with CF with and without known cystic fibrosis related diabetes (CFRD) who had acute myocardial infarction (AMI) requiring coronary stent placement. This was a heterogeneous group of patients, without a clear pattern of consistent risk factors. Interestingly, most patients in this cohort had low LDL. In this review, we discuss risk factors of cardiovascular disease (CVD) that may apply to the CF population. While CAD is rare in people with CF, it does occur. We postulate that the risk will grow with increased longevity and the increased prevalence of co-morbidities such as obesity and dyslipidemia.
© 2022 Published by Elsevier Inc.

Entities:  

Keywords:  Coronary artery disease; Cystic fibrosis; Cystic fibrosis related diabetes; Hyperlipidemia; Low cholesterol level; Risk factors

Year:  2022        PMID: 36267108      PMCID: PMC9576554          DOI: 10.1016/j.jcte.2022.100308

Source DB:  PubMed          Journal:  J Clin Transl Endocrinol        ISSN: 2214-6237


  22 in total

Review 1.  The heart in cystic fibrosis.

Authors:  Rowland J Bright-Thomas; A Kevin Webb
Journal:  J R Soc Med       Date:  2002       Impact factor: 5.344

2.  Ischaemic heart disease--a new issue in cystic fibrosis?

Authors:  Felicity M R Perrin; Walter Serino
Journal:  J R Soc Med       Date:  2010-07       Impact factor: 5.344

3.  Elexacaftor-Tezacaftor-Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele.

Authors:  Peter G Middleton; Marcus A Mall; Pavel Dřevínek; Larry C Lands; Edward F McKone; Deepika Polineni; Bonnie W Ramsey; Jennifer L Taylor-Cousar; Elizabeth Tullis; François Vermeulen; Gautham Marigowda; Charlotte M McKee; Samuel M Moskowitz; Nitin Nair; Jessica Savage; Christopher Simard; Simon Tian; David Waltz; Fengjuan Xuan; Steven M Rowe; Raksha Jain
Journal:  N Engl J Med       Date:  2019-10-31       Impact factor: 91.245

4.  Assessment of safety and efficacy of long-term treatment with combination lumacaftor and ivacaftor therapy in patients with cystic fibrosis homozygous for the F508del-CFTR mutation (PROGRESS): a phase 3, extension study.

Authors:  Michael W Konstan; Edward F McKone; Richard B Moss; Gautham Marigowda; Simon Tian; David Waltz; Xiaohong Huang; Barry Lubarsky; Jaime Rubin; Stefanie J Millar; David J Pasta; Nicole Mayer-Hamblett; Christopher H Goss; Wayne Morgan; Gregory S Sawicki
Journal:  Lancet Respir Med       Date:  2016-12-21       Impact factor: 30.700

5.  Abnormal lipid concentrations in cystic fibrosis.

Authors:  Veronica Figueroa; Carlos Milla; Elizabeth J Parks; Sarah Jane Schwarzenberg; Antoinette Moran
Journal:  Am J Clin Nutr       Date:  2002-06       Impact factor: 7.045

6.  Diabetes-related mortality in adults with cystic fibrosis. Role of genotype and sex.

Authors:  Connor Lewis; Scott M Blackman; Amanda Nelson; Ewa Oberdorfer; Daniel Wells; Jordan Dunitz; William Thomas; Antoinette Moran
Journal:  Am J Respir Crit Care Med       Date:  2015-01-15       Impact factor: 21.405

7.  Azithromycin and tezacaftor/ivacaftor is associated with first-degree heart block in an adult with cystic fibrosis.

Authors:  Yang Song; Alexandra Coronel Palacios; Aravinda Thiagalingam; Peter G Middleton
Journal:  J Cyst Fibros       Date:  2020-08-05       Impact factor: 5.482

8.  Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial.

Authors:  Harry G M Heijerman; Edward F McKone; Damian G Downey; Eva Van Braeckel; Steven M Rowe; Elizabeth Tullis; Marcus A Mall; John J Welter; Bonnie W Ramsey; Charlotte M McKee; Gautham Marigowda; Samuel M Moskowitz; David Waltz; Patrick R Sosnay; Christopher Simard; Neil Ahluwalia; Fengjuan Xuan; Yaohua Zhang; Jennifer L Taylor-Cousar; Karen S McCoy
Journal:  Lancet       Date:  2019-10-31       Impact factor: 79.321

9.  Clinical care guidelines for cystic fibrosis-related diabetes: a position statement of the American Diabetes Association and a clinical practice guideline of the Cystic Fibrosis Foundation, endorsed by the Pediatric Endocrine Society.

Authors:  Antoinette Moran; Carol Brunzell; Richard C Cohen; Marcia Katz; Bruce C Marshall; Gary Onady; Karen A Robinson; Kathryn A Sabadosa; Arlene Stecenko; Bonnie Slovis
Journal:  Diabetes Care       Date:  2010-12       Impact factor: 19.112

10.  Potentiators (specific therapies for class III and IV mutations) for cystic fibrosis.

Authors:  Mica Skilton; Ashma Krishan; Sanjay Patel; Ian P Sinha; Kevin W Southern
Journal:  Cochrane Database Syst Rev       Date:  2019-01-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.